Logo image
A30 Biomarkers In Thoracic Oncology: Predicting Outcomes: Serum CXCL16 As A Potential Prognostic Marker In Advanced Non Small Cell Lung Cancer
Journal article   Peer reviewed

A30 Biomarkers In Thoracic Oncology: Predicting Outcomes: Serum CXCL16 As A Potential Prognostic Marker In Advanced Non Small Cell Lung Cancer

Y. Shibata, 隆昭 佐藤, M. Ikeda, H. Sasaki, A. Nagashima, R. Ushio, K. Nakashima, H. Watanabe, K. Nagai, K. Tashiro, …
American Journal of Respiratory and Critical Care Medicine, Vol.195
2017

Abstract

Biomarker;Lung cancer;CXCL16;Prognosis;Non-small-cell lung carcinoma

Corresponding author's email: planloser_igel@hotmail.co.jp Rationale: We have shown that CXCL16, a chemokine involved in angiogenesis and tumor metastasis, was elevated in the serum of patients with advanced nonsmall cell lung cancer (NSCLC) (ATS2015 abstr. Patients received 1st line chemotherapy of platinum-doublet with or without anti-VEGF antibody, Bevacizumab, or epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor according to histology and EGFR-mutation status.

Metrics

1 Record Views

Details

Logo image